For the Quarter Ending December 2025
North America
• In USA, the Cefuroxime Price Index rose by 1.04% quarter-over-quarter, reflecting marginal import cost increases.
• The average Cefuroxime price for the quarter was approximately USD 131855.00/MT, reflecting landed-cost change modestly.
• Stable imports kept the Cefuroxime Spot Price steady while margins tracked Cefuroxime Production Cost Trend.
• Cefuroxime Price Forecast shows narrow ranges as freight reductions offset modest upstream input firmness recently.
• Seasonal restocking supports the Cefuroxime Demand Outlook and keeps the Cefuroxime Price Index broadly steady.
• Inventory remained moderate at wholesalers, limiting upside for Cefuroxime Spot Price despite importer allocations currently.
• Export supply discipline from Asia and FDA oversight stabilized volumes, supporting the Cefuroxime Price Index.
• Manufacturers and importers expect measured procurement, aligning with the Cefuroxime Price Forecast and stable demand.
Why did the price of Cefuroxime change in December 2025 in North America?
• Reduced Trans-Pacific freight and steady Asian API exports lowered landed costs, tempering upward pressure seasonally.
• Chinese environmental inspections trimmed some export offers while West Coast port operations preserved arrivals timely.
• Hospital restocking and GPO pricing caps balanced procurement, sustaining marginal price increases without triggering volatility.
APAC
• In China, the Cefuroxime Price Index rose by 1.5% quarter-over-quarter, supported by export procurement demand.
• The average Cefuroxime price for the quarter was approximately USD 132333.33/MT, reflecting export and domestic contracts.
• Cefuroxime Spot Price remained pressured in December as ample export-oriented supply slightly outpaced incremental overseas enquiry.
• Cefuroxime Price Forecast signals narrow, mildly soft trading into early quarter absent significant demand improvement.
• Cefuroxime Production Cost Trend was stable as 7-ACA availability and energy tariffs exerted minimal upward pressure.
• Cefuroxime Demand Outlook remains steady with hospital tender caps limiting domestic upside while supporting exports.
• Cefuroxime Price Index showed marginal quarterly gain while inventories rose and exporters trimmed offers defensively.
• Major Chinese plants maintained sub-seventy percent operating rates, constraining volatility while keeping export supply adequate.
Why did the price of Cefuroxime change in December 2025 in APAC?
• Exports outpaced incremental enquiries in December, creating mild oversupply pressure on FOB quotations and offers.
• Stable 7-ACA feedstock and unchanged energy tariffs limited production cost increases, reducing upward price momentum.
• Port operations remained fluid and currency movements provided no advantage, prompting exporters to concede discounts.
Europe
• In Germany, the Cefuroxime Price Index rose by 1.47% quarter-over-quarter, reflecting marginal import cost increases.
• The average Cefuroxime price for the quarter was approximately USD 132418.33/MT, according to trade statistics.
• Cefuroxime Spot Price remained muted in December due to moderate inventories and reduced spot buying.
• Cefuroxime Price Forecast indicates range-bound near-term pricing, contingent on logistics and stewardship-driven hospital procurement patterns.
• Cefuroxime Production Cost Trend rose from higher 7-ACA and energy-related compliance costs, pressuring export offers.
• Cefuroxime Demand Outlook remains seasonally supportive from hospital tenders while stewardship protocols limit volume growth.
• Cefuroxime Price Index reflected import-cost pass-through, freight uplifts and comfortable inventories, preventing upward pricing moves.
• Asian exporters maintained operating rates, prioritised US orders, narrowing German availability and supporting CFR Hamburg.
Why did the price of Cefuroxime change in December 2025 in Europe?
• Balanced import flows and unchanged Asian offers kept landed costs stable, limiting December price pressure.
• Hospital purchasers covered fourth-quarter needs, reducing spot inquiries and weakening sellers' demand for higher premiums.
• Freight and logistics eased in Hamburg, while comfortable wholesaler stocks reduced urgency, nudging prices lower.
For the Quarter Ending September 2025
North America
• In USA, the Cefuroxime Price Index fell by 3.56% quarter-over-quarter, reflecting exporter discounting and inventory.
• The average Cefuroxime price for the quarter was approximately USD 130496.67/MT, reflecting elevated landed costs.
• Cefuroxime Spot Price softened as US buyers reduced orders, leaving elevated inventories and strained liquidity.
• Cefuroxime Price Forecast points to volatility, with potential stabilization as replenishment increases and inventories normalize.
• Cefuroxime Production Cost Trend eased due to lower upstream input prices, supporting exporter margin recovery.
• Cefuroxime Demand Outlook remains steady, anchored by hospital and clinical usage despite conservative pharmaceutical procurement.
• Freight rate declines and episodic congestion created landed cost signals, supporting the Cefuroxime Price Index.
• Scheduled maintenance and seasonal procurement could tighten supply briefly, mildly lifting the Cefuroxime Price Index.
Why did the price of Cefuroxime change in September 2025 in North America?
• Oversupply from major Asian exporters pressured discounts, increasing US inventories and sustaining downward price pressure.
• Falling freight rates followed by port congestion created inconsistent landed costs, confusing importer procurement decisions.
• Buyer caution amid tariff uncertainties and high inventories suppressed spot demand, limiting upward price momentum.
APAC
• In China, the Cefuroxime Price Index fell by 3.47% quarter-over-quarter, driven by oversupply and weak demand.
• The average Cefuroxime price for the quarter was approximately USD 130400.00/MT, reflecting subdued domestic demand.
• Cefuroxime Spot Price rallied briefly during operational disruptions, yet overall Price Index remained subdued amid inventory overhang.
• Cefuroxime Production Cost Trend shows downward pressure from cheaper raw materials, partly offset by elevated logistics expenses.
• Cefuroxime Demand Outlook remains weak as PMI contraction and export tariffs suppressed new orders and downstream offtake.
• Cefuroxime Price Forecast suggests modest volatility with intermittent upticks due to maintenance and occasional forward buying.
• High inventories and tariff-driven export disruptions pressured domestic margins, influencing the Cefuroxime Price Index trajectory negatively.
• Major producer maintenance temporarily tightened supply, but smaller manufacturers increased volumes, keeping spot markets and Price Index soft.
Why did the price of Cefuroxime change in September 2025 in APAC?
• Temporary plant maintenance reduced available exports while domestic inventories remained elevated, creating mixed supply signals.
• Logistics disruptions and port congestion increased distribution costs, contributing to localized tighter supply and upward price pressure.
• Weak pharmaceutical demand, PMI contraction and high inventories suppressed selling prices despite periodic forward buying and short-term restocking.
Europe
• In Germany, the Cefuroxime Price Index fell by 3.51% quarter-over-quarter, driven by ample inventories nationally.
• The average Cefuroxime price for the quarter was approximately USD 130503.67/MT, according to reported data.
• Cefuroxime Spot Price volatility eased as German distributors prioritized inventory liquidation, compressing Price Index movements.
• Cefuroxime Production Cost Trend softened amid lower energy and input costs, supporting margins for manufacturers.
• Cefuroxime Demand Outlook for hospitals remained subdued, with buyers exercising cautious procurement and prioritizing inventories.
• Cefuroxime Price Forecast indicates modest near-term weakness, with slight recovery potential as logistics gradually normalize.
• Elevated inventories and muted export demand kept the Cefuroxime Price Index anchored despite logistical pressures.
• Chinese supply remained ample, while producers offered discounted volumes, exerting downward pressure on spot markets.
Why did the price of Cefuroxime change in September 2025 in Europe?
• Persistent inventory overhang from earlier procurement waves reduced spot purchases, pressuring prices downward in September.
• Shipping delays and elevated logistics costs supported prices, but delayed peak surcharges limited import-driven spikes.
• Subdued downstream demand and cautious procurement strategies by hospitals and manufacturers constrained upward price momentum.
For the Quarter Ending June 2025
North America
• Q2 2025 saw a mixed trajectory in North American Cefuroxime spot prices, starting with a significant decline in April (-4.90%), a sharp rebound in May (+0.19%), and stabilizing with a slight downturn in June (-0.23%)—averaging roughly a 1.65% net downward fluctuation across the quarter.
• Prices in June 2025 declined notably due to oversupply from increased production in China and India, coupled with cautious procurement owing to tariff uncertainty.
• April’s price drop was driven by weak demand and trade policy uncertainties, including high U.S. tariffs on Chinese imports that disrupted trade flows and increased domestic inventories. In May, a tariff suspension triggered a surge in freight demand, causing logistical bottlenecks and temporary price hikes. June saw aggressive exporter price cuts amid inventory gluts and tariff risks.
• Consistently modest demand in April was followed by strong pharmaceutical procurement in May to rebuild safety stocks amid trade tensions. June demand remained stable but subdued due to buyers relying on existing stocks amid ongoing uncertainties and logistical challenges.
• U.S. tariffs, peaking at 145% on Chinese pharmaceutical imports from April 2025, influenced production costs and pricing strategies, pressuring manufacturers to balance supply and demand.
• High ocean freight costs and port congestion contributed to price volatility within Q2. May's freight surge was countered by improved shipping capacity but persistent delays.
• Continued reliance on Cefuroxime for bacterial infections reinforced baseline demand, especially in hospital and outpatient settings, despite market pricing pressures.
• Given tariff complexities and supply gluts, price recovery may be limited in the short term; volatility is likely to persist through Q3 2025.
• Rising production costs, driven by regulatory compliance and import tariffs, challenged manufacturers, but supply capacity remained sufficient to meet demand.
• Cautious buyer behavior amid macroeconomic uncertainty and trade policies dominated, reinforcing a buyer's market for Cefuroxime APIs in North America.
Asia Pacific
• Cefuroxime price index in APAC displayed a generally stable to slight downward trend with April (-4.93%), a minor uptick in May (+0.19%), and a small decrease in June (-0.18%). The quarterly average fluctuation stood near 1.64% down.
• June saw notable price decreases due to intense domestic price competition, PPI deflation (-3.6% YoY), and persistent overcapacity, particularly in China, the region's major producer.
• April’s price pressures stemmed from reduced domestic consumption and export challenges from U.S.-China tariffs. May temporarily reversed this with strong export demand and logistics strain due to tariff reprieves and order surges. Maintenance shutdowns and shifting production shares among manufacturers influenced June’s supply dynamics.
• April and June saw subdued demand linked to macroeconomic weakness and industry overcapacity, while May witnessed a resurgence in global buying, particularly from the U.S. in anticipation of tariff expirations.
• The U.S.-China trade tensions, with tariffs up to 245%, constrained export flow and incentivized aggressive pricing among Chinese producers to maintain competitiveness internationally.
• May’s sharp rise in spot container shipping rates (+27%) driven by increased transpacific cargo flows contributed to upward price pressure.
• Despite rising logistics costs, overall manufacturing costs faced downward pressure due to overcapacity and price wars among producers.
• Chinese government concern about excessive price competition remains, but corrective measures are limited, sustaining volatile pricing.
• APAC is expected to face ongoing price pressure until demand recovers and supply balances, with possible stabilization after the temporary tariff reprieve ends in August 2025.
• Pharmaceutical applications dominate demand, but subdued consumer purchasing power and manufacturing sluggishness continue to weigh on spot price momentum despite Cefuroxime’s clinical importance.
Europe
• The European Cefuroxime market exhibited a generally downward trend with prices dropping sharply in April (-4.90%), a mild increase in May (+0.18%), and another decline in June (-0.25%), equating to an average 1.65% overall decrease for Q2.
• June's price drop was driven by ample inventories from early acquisitions, low inflation, and logistical constraints delaying spot market activity and purchase urgency.
• April and May saw oversupply due to diverted Chinese shipments from the U.S. market and front-loaded European stocking before public holidays, stressing inventories. Freight congestion and port bottlenecks in Northern Europe added delivery delays.
• April and June demand remained cautious and inventory-driven rather than consumption-led. Pharmaceutical and secondary downstream sectors awaited market clarity, limiting new order volumes.
• The temporary removal of U.S. tariffs diverted Asian exports towards Europe, swelling local supply and exerting downward pressure on prices.
• Low monthly inflation (~2.0% YoY in June) and soft PMI readings (50.4 in June) suggested a cooling economy dampening buying enthusiasm.
• Port operational issues in Hamburg, Rotterdam, and Antwerp caused persistent delays, compounding supply-demand mismatches and price weakness.
• Stability in API supply from Asia was maintained, but slow uptake and inventory liquidation strategies dominated market behavior.
• Prices are expected to remain subdued in the near term, with potential for stabilization only after inventory normalizations and logistical improvements.
• Pharmaceutical buyers, hospitals, and generic manufacturers focused on inventory rationalization rather than expansion, moderating demand and supporting a soft price environment.
For the Quarter Ending March 2025
North America
In the first quarter of 2025, Cefuroxime prices in the United States experienced a mixed trajectory, beginning the year with notable gains before declining steadily through February and March. In January, the market witnessed strong upward momentum in Cefuroxime prices, primarily fueled by robust pharmaceutical demand, supply constraints, and elevated freight costs. Producers strategically optimized output amid ongoing logistical challenges, including congestion at the Port of Los Angeles and labor shortages, which increased clearance times and demurrage costs. Additionally, global shipping disruptions and inflationary pressures pushed up import prices, prompting buyers to secure stocks at higher rates in anticipation of further market instability.
However, by February, the market dynamic shifted as Cefuroxime prices began to decline. The dip was largely attributed to subdued demand, elevated inventories, and improved logistics following front-loaded imports from China ahead of the Lunar New Year. Downstream buyers adopted a cautious procurement strategy, opting to manage existing stockpiles instead of making fresh purchases. At the same time, a sharp drop in transpacific freight rates made imported supplies more cost-effective, intensifying price competition. Economic uncertainty, coupled with tariff-related speculation under the Trump administration, further weighed on market sentiment, causing buyers to adopt a conservative approach and delay procurement decisions.
The downward trend continued into March, with Cefuroxime prices facing further pressure due to persistent oversupply and soft demand. Despite stable production levels in China, U.S. inventories remained high due to earlier stockpiling, discouraging new purchases. The depreciation of the U.S. dollar and escalating tariff risks on Chinese and Indian imports heightened buyer concerns, leading to widespread delays and cancellations of shipments. Although improved vessel availability and falling shipping costs enhanced logistics, the overall demand environment remained weak amid inflationary pressures and slowing economic growth. As a result, Cefuroxime prices declined consistently throughout Q1 2025, with market participants maintaining a cautious stance in response to evolving trade and economic conditions.
Asia Pacific
In Q1 2025, Chinese Cefuroxime prices shifted from an initial rise to a persistent decline, shaped by macro-economic factors, trade dynamics, seasonal disruptions, and supply-demand fundamentals. January saw export prices increase due to intensified global procurement ahead of anticipated U.S. tariff changes. Chinese suppliers, recovering from destocking and facing rising freight rates and Lunar New Year constraints, adjusted prices upward, influenced by mild raw material cost increases and China’s rising CPI. Strong pharmaceutical and nutraceutical demand initially supported prices despite a contracting manufacturing PMI (49.1).
However, by February, oversupply and weakened domestic and international demand caused a sharp price correction. Key importers with high inventories reduced purchases, and prolonged Lunar New Year holidays disrupted output and trade. U.S.-China trade tensions further limited exports, increasing the domestic surplus. A deflationary environment and declining CPI reflected weakening economic momentum, especially in pharmaceuticals.
The downward trend continued in March, driven by favorable supply and weak demand. Yuan appreciation and a -0.7% deflation rate lowered production costs. Improved port logistics did little to offset subdued demand. Post-holiday inventory liquidation intensified competition and price cuts. Soft consumer and industrial demand post-overproduction compelled manufacturers to offer incentives. Overall, Q1 2025 saw a quarter-over-quarter decline, with January's peak followed by February and March drops, highlighting the need for synchronized forecasting and agile pricing in a volatile environment.
Europe
The German Cefuroxime market experienced a generally downward trend in Q1 2025. An initial small price increase in January, due to European manufacturers buying ahead of anticipated Lunar New Year production issues in Asia, was followed by consistent price declines in February and March. This downturn stemmed from reduced demand after early stockpiling and high inventory levels in pharmaceutical and food sectors.
Improved Cefuroxime production, stable imports, and significantly lower ocean freight rates, particularly after the Lunar New Year and the cancellation of the Europe Peak Season Surcharge (PSS), contributed to ample supply. The strengthening Euro further reduced import costs. By March's end, the market had soft prices due to sufficient supply, weak demand, and favorable economic conditions.
Buyers were cautious, delaying purchases until Q2. The market enters Q2 2025 with high inventories and a cautious demand forecast, suggesting a focus on inventory reduction. While supply is expected to remain good, demand recovery is crucial for price stabilization in the next quarter. Market participants should monitor consumer sentiment, political events, and potential logistics disruptions.
